SCHEMBL31546384

SCHEMBL31546384

O=C(NCC1(CN2CCC(Cc3ccccn3)CC2)CC1)N1CCN(c2nc(-c3ccc(OC(F)(F)F)cc3)no2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.44
▸ MAPT P10636 5/20 0.44
▸ TP53 P04637 4/20 0.44
▸ HTT P42858 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ CHRM4 P08173 3/20 0.42
▸ THRB P10828 1/20 0.39
▸ SMO Q99835 3/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ EPHX2 P34913 3/20 0.37
▸ HDAC4 P56524 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ DPP4 P27487 1/20 0.37
▸ DPP7 Q9UHL4 1/20 0.37
▸ CHRM2 P08172 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30584805 0.89 LMNA (0.48) LMNAMAPTTP53HTTALDH1A1
SCHEMBL31667422 0.88 LMNA (0.45) LMNAMAPTTP53HTTALDH1A1
SCHEMBL25434754 0.81 MEN1 (0.56) LMNAMAPTTP53HTTALDH1A1
SCHEMBL30584727 0.79 LMNA (0.47) LMNAMAPTTP53HTTALDH1A1
SCHEMBL31667543 0.79 LMNA (0.58) LMNAMAPTTP53HTTALDH1A1
SCHEMBL30584775 0.79 LMNA (0.49) LMNAMAPTTP53HTTALDH1A1
SCHEMBL30584882 0.78 LMNA (0.46) LMNAMAPTTP53HTTALDH1A1
Formic Acid SCHEMBL31546410 0.77 LMNA (0.56) LMNAMAPTTP53HTTALDH1A1
SCHEMBL31546341 0.77 EPHX2 (0.49) LMNAMAPTTP53HTTALDH1A1
SCHEMBL31546427 0.77 TSHR (0.50) LMNAMAPTTP53HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 LMNA 1344/4885MAPT 2999/4885TP53 54/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 LMNA 1344/4885MAPT 2999/4885TP53 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback